Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Chugai Pharmaceutical Co., Ltd.    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD.

(4519)
  Report  
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Chugai Pharmaceutical : Wins Prize in 7th WICI Japan Award for Excellence in Integrated Reporting

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/18/2019 | 06:12am EST

TOKYO - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that its 'Annual Report 2018' has been awarded a Prize for Excellence in Integrated Reporting in the 7th WICI Japan Award for Excellence in Integrated Reporting.

Chugai's Annual Report was recognized as an excellent example of integrated reporting with a high level of thoroughness that presents a good view of the company's future. This marks the first time for Chugai to receive a WICI Japan award.

WICI Japan, the Japanese arm of the World Intellectual Capital/Assets Initiative (WICI), is responding to the initiatives of the International Council for Integrated Reporting (IIRC), which aims to improve the sustainability of business entities and society by improving interactive communications between companies and their stakeholders through clear and concise reports on business activities. The Award for Excellence in Integrated Reporting was established in 2013 by WICI Japan as a measure to promote the publication of integrated reports in Japan.

Candidates for this year's prizes were selected from the top 300 companies in terms of market capitalization as of the end of August 2019 on the First Section of the Tokyo Stock Exchange and also an additional 214 companies who were judged to have issued integrated annual reports. The results of the review by WICI Japan are as follows: 1 winner of The Best Integrated Reporting Grand Prize; 4 winners of The Excellence in Integrated Reporting Prize and 1 winner of the Integrated Reporting Award.

Chugai's Annual Report has continually earned high acclaim, receiving an award every year since Annual Report 2012 in the NIKKEI Annual Report Awards, winning the Grand Prize for two consecutive years for Annual Report 2014 and Annual Report 2015, and Second Prize for Annual Report 2017.

Chugai will continue to disclose information in ways that are even easier-to-understand in order to satisfy as many stakeholders as possible.

Contact:

Tomoko Shimizu

Tel: +81-3-3273-0881

Email: pr@chugai-pharm.co.jp

(C) 2019 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
CHUGAI PHARMACEUTICAL CO., LTD. 2.02% 10040 End-of-day quote.62.46%
ROCHE HOLDING AG -0.60% 300.55 Delayed Quote.24.22%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CHUGAI PHARMACEUTICAL CO.,
12/10CHUGAI PHARMACEUTICAL : Nemolizumab Receives FDA Breakthrough Therapy Designatio..
AQ
12/09CHUGAI PHARMACEUTICAL : Let's Learn about Cancer Genomic Medicine, Chugai's Webs..
AQ
12/05CHUGAI PHARMACEUTICAL : R&I Raises Chugai's Issuer Rating from 'AA -' to 'AA'
AQ
12/02CHUGAI PHARMACEUTICAL : Completes Transfer of Rights to Maruho for Oxarol Ointme..
AQ
11/29CHUGAI PHARMACEUTICAL : Results from Phase III SAkuraSky Study for Chugai's Satr..
AQ
11/28CHUGAI PHARMACEUTICAL : Results from Phase III SAkuraSky Study for Chugai's Satr..
BU
11/28Chugai and JW Pharmaceutical Agree to Make C&C Research Laboratories, a Joint..
AQ
11/27CHUGAI PHARMACEUTICAL : Launches Tecentriq Intravenous Infusion 840 mg as an Opt..
AQ
11/21CHUGAI PHARMACEUTICAL : Receives Orphan Drug Designation for Polatuzumab vedotin..
AQ
11/18CHUGAI PHARMACEUTICAL : Wins Prize in 7th WICI Japan Award for Excellence in Int..
AQ
More news
Financials (JPY)
Sales 2019 685 B
EBIT 2019 219 B
Net income 2019 166 B
Finance 2019 269 B
Yield 2019 1,25%
P/E ratio 2019 33,2x
P/E ratio 2020 31,4x
EV / Sales2019 7,63x
EV / Sales2020 7,31x
Capitalization 5 496 B
Technical analysis trends CHUGAI PHARMACEUTICAL CO.,
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 14
Average target price 8 761,54  JPY
Last Close Price 10 040,00  JPY
Spread / Highest target 13,5%
Spread / Average Target -12,7%
Spread / Lowest Target -32,3%
EPS Revisions
Managers
NameTitle
Tatsuro Kosaka President, CEO & Representative Director
Osamu Nagayama Chairman
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Hisanori Takanashi Executive Officer & GM-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
CHUGAI PHARMACEUTICAL CO., LTD.62.46%49 321
JOHNSON & JOHNSON9.24%371 989
ROCHE HOLDING AG24.22%261 794
MERCK AND COMPANY17.22%228 044
PFIZER-11.71%213 285
NOVARTIS22.85%209 621